ArriVent BioPharma (AVBP) Insider Parsey Buys 13,562 Shares
Merdad Parsey, alongside other insiders, bought shares of AVBP, signaling internal confidence.
Reviewed by automated data checks against the source filing. How we make and check alerts
Merdad Parsey bought 13,562 shares of ArriVent BioPharma, Inc. ($AVBP) on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $AVBP is up 6.6% after 1 week, down 11.1% after 1 month and down 47.5% to date (from the $31.74 close on Jun 18, 2026).
AVBP
ArriVent BioPharma, Inc.
Key Points
- On June 18, 2026, Merdad Parsey purchased 13,562 shares of AVBP, joining other insiders in similar transactions.
- AVBP shares traded at $31.74 on Tuesday, with institutional investors like Suvretta Capital Management increasing their positions.
- Analysts from Truist Securities and Citigroup maintain a 'buy' rating on AVBP, with price targets up to $50.
Get $AVBP trade alerts by text
We text you when insiders, Congress or big funds trade $AVBP. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ArriVent BioPharma, Inc. alert may contain errors. Disclosures
Merdad Parsey acquired 13,562 shares of AVBP on June 18, 2026. This purchase was part of a series of insider transactions that day, where several insiders bought the same amount of shares. These transactions were not planned under any Rule 10b5-1 trading plans.
Other Institutional Activity in AVBP
Suvretta Capital Management added 295,048 shares to its holdings, bringing its total to 4,401,083 shares worth approximately $101.5 million, reflecting a 7.2% increase. Infinitum Asset Management also boosted its position by 25,000 shares, now holding 4,148,923 shares valued at about $95.7 million, marking a 0.6% increase. Meanwhile, FMR LLC trimmed its stake by 687,440 shares, reducing its holdings by 18.6% to 3,016,132 shares, valued at around $69.6 million.
ArriVent BioPharma, Inc. Stock Up 13.1%
Shares of AVBP traded at $31.74 on Tuesday. The stock is part of a competitive sector, with a diverse range of institutional investors involved. The market activity reflects continued interest and varied strategies among large investors.
Insider Buying and Selling at ArriVent BioPharma, Inc.
On June 18, 2026, several insiders, including Chris Nolet, Kristine Peterson, John Hohneker, and Merdad Parsey, each purchased 13,562 shares of AVBP. These transactions indicate a unified move by company insiders to increase their stakes. Earlier in the year, on February 2, 2026, James Paul Kastenmayer, General Counsel, and Winston Kung, Chief Financial Officer, bought 130,000 and 140,000 shares, respectively.
Analysts Set New Price Targets
Truist Securities maintained its 'buy' rating for AVBP on May 29, 2026, with a price target of $45. Citigroup also maintained a 'buy' rating with a target of $43 on May 13, 2026. B. Riley Securities and Oppenheimer reiterated 'buy' ratings with targets of $45 and $50, respectively, earlier in the year. The consensus among analysts is positive, with a strong 'buy' recommendation.
Bottom Line
The recent insider purchases at AVBP, including Merdad Parsey's acquisition, suggest confidence from those within the company. Institutional investors are actively adjusting their holdings, indicating varied strategies and outlooks. Analysts continue to support AVBP with strong 'buy' ratings and optimistic price targets, reflecting positive sentiment in the market.
Related Filing Alerts
Source: Merdad Parsey's Form 4 filing on $AVBP (Jun 18, 2026). Find the original filing: AVBP Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts